neuroscientist studied schizophrenia decades convinced similar successes medicines shelves hold untapped promise treating brain diseases pharmaceutical companies prompted share data scientists existing drug passed fda tests prove nontoxic humans successfully repurposing half estimated 13 years significantly average $ 2 billion $ 3 billion cost developing single drug scratch thousands fda approved drugs represent vast resource potentially modified target number conditions potential largely unexplored companies focus specific diseases restructure r&d programs look thousands drugs fda approved stalled clinical trials discontinued drugmakers company abandons development drug researchers know locked company files lost scientists need access information need starting early 2010s u.s. national